ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Shionogi & Co., Ltd.

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2021 JPYUSD
Gross Profit238,000M2,244.06M
Operating income95,694M902.28M
Income before tax143,018M1,348.49M
Net income111,858M1,054.69M
Diluted EPS364.883.44
Dividends Per Share1081.01
Total Assets998,992M9,040.65M
Total liabilities134,156M1,214.08M
Total equity846,108M7,657.08M
Operating cash flow109,039M1,028.11M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 338,890M 344,667M 367,960M 333,371M 297,177M
Gross Profit 261,113M 270,756M 305,713M 270,117M 238,000M
Operating income 108,179M 115,219M 168,370M 130,609M 95,694M
Income before tax 122,695M 137,378M 174,043M 158,516M 143,018M
Net income 83,878M 108,866M 137,190M 122,193M 111,858M
EBITDA 124,519M 134,226M 187,074M 144,649M 110,403M
Diluted EPS 255.87 337.42 434.70 395.28 364.88
Dividends Per Share 72 82 94 103 108
Total Assets 670,271M 711,463M 938,540M 873,695M 998,992M
Total liabilities 144,058M 106,619M 125,125M 108,186M 134,156M
Total equity 522,737M 601,374M 808,774M 765,152M 846,108M
Operating cash flow 111,903M 129,790M 165,000M 131,940M 109,039M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 3,129.53M 3,109.80M 3,318.10M 3,066.16M 2,802.03M
Gross Profit 2,411.29M 2,442.93M 2,756.78M 2,484.38M 2,244.06M
Operating income 998.99M 1,039.57M 1,518.28M 1,201.26M 902.28M
Income before tax 1,133.04M 1,239.51M 1,569.44M 1,457.94M 1,348.49M
Net income 774.58M 982.25M 1,237.11M 1,123.86M 1,054.69M
EBITDA 1,149.89M 1,211.07M 1,686.95M 1,330.40M 1,040.97M
Diluted EPS 2.36 3.04 3.92 3.63 3.44
Dividends Per Share 0.66 0.73 0.84 0.94 1.01
Total Assets 6,015.17M 6,689.82M 8,479.37M 8,093.14M 9,040.65M
Total liabilities 1,292.81M 1,002.52M 1,130.46M 1,002.13M 1,214.08M
Total equity 4,691.16M 5,654.66M 7,306.98M 7,087.69M 7,657.08M
Operating cash flow 1,033.38M 1,171.04M 1,487.89M 1,213.51M 1,028.11M

Valuation Measures

Mar 2021
Operating margin32.20%
Profit margin37.64%

Key executives

  • President & Representative Director: Isao Teshirogi
  • Director & Executive Vice President: Takuko Sawada
  • Executive Officer: Takeshi Shiota
  • Executive Officer: Miyuki Hiura
  • Executive Officer & Personnel Manager: Noriyuki Kishida


  • Nomura Asset Management Co., Ltd. (6.8%)
  • Sumitomo Life Insurance Co. (5.9%)
  • Shionogi & Co., Ltd. (3.2%)
  • Sumitomo Mitsui Banking Pension Fund (3.0%)
  • Nikko Asset Management Co., Ltd. (2.8%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • Nippon Life Insurance Co. (2.6%)
  • The Vanguard Group, Inc. (2.3%)
  • Ping An Insurance (Group) Co. of China Ltd. (2.0%)
  • Capital International KK (1.9%)

Contact Details

Related Companies

  • Shionogi Singapore Pte Ltd.
  • Shionogi Marketing Solutions Co., Ltd.
  • Shionogi Pharmacovigilance Center Co., Ltd.
  • Shionogi Business Partner Co., Ltd.
  • Shionogi Digital Science Co., Ltd
  • Shionogi Career Development Center Co., Ltd.
  • Shionogi TechnoAdvance Research Co., Ltd.
  • Shionogi BV
  • Shionogi Pharma Co., Ltd.
  • Shionogi Healthcare Co. Ltd.
  • Shionogi & Co., Ltd. /2 Subsidiaries/
  • Shionogi & Co. Restricted Stock Compensation Plan
  • Shionogi Healthcare & Co., Ltd.
  • Pionnier KK
  • Shionogi USA Holdings, Inc.
  • Beijing Shionogi Pharmaceutical Technology Ltd.
  • Shionogi Ltd.
  • Ezose Sciences, Inc.
  • Shionogi, Inc.
  • Shionogi Institute for Medical Science
  • Aburahi Laboratories
  • Taiwan Shionogi & Co., Ltd.
  • Shionogi Pharma Chemicals Co., Ltd.
  • Shionogi General Service Co., Ltd.
  • Shionogi Bunseki Center KK
  • Shionogi Ireland Ltd.
  • Shionogi Engineering Service Co. Ltd.
  • UMN Pharma, Inc.
  • Shionogi Bioresearch Corp.
  • Shionogi & Co. Ltd. Pension Fund


  • CytoDyn Inc.
  • Vaxart, Inc.
  • NanoViricides, Inc.
  • Entasis Therapeutics Holdings, Inc.
  • Trevi Therapeutics, Inc.
  • Nabriva Therapeutics Plc
  • Spero Therapeutics, Inc.
  • TaiMed Biologics Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cocrystal Pharma Inc
  • Iterum Therapeutics plc
  • Vir Biotechnology, Inc.
  • Acura Pharmaceuticals, Inc.
  • aTyr Pharma, Inc.
  • Arbutus Biopharma Corporation
  • BELLUS Health Inc.
  • Surface Oncology, Inc.
  • Terns Pharmaceuticals, Inc.
  • Zynerba Pharmaceuticals Inc
Last Updated on 13 May, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more